title: Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study.
abstract: The objective of this prospective, randomised study was to compare the efficacy, safety and tolerability of vaginal micronised progesterone with oral dydrogesterone as luteal phase support after in-vitro fertilisation (IVF). A total of 430 women underwent IVF/intracytoplasmic sperm injection (ICSI) treatment. Long protocol gonadotropin releasing hormone analogue down-regulation was followed by gonadotropin stimulation. Human chorionic gonadotropin was given when two or more follicles reached > or = 17 mm. After 36 h, oocytes were retrieved and IVF was performed. Embryo transfer was done at the 4-8 cell embryo stage. Luteal support was initiated from the day of embryo transfer and continued for up to 14 days. Patients were randomised to luteal supplementation with either intravaginal micronised progesterone 200 mg three times daily (n=351) or oral dydrogesterone 10 mg twice daily (n=79). In cases of a positive pregnancy test, luteal support was continued for 12 weeks. Both dydrogesterone and micronised progesterone were associated with similar rates of successful pregnancies. Vaginal discharge or irritation were reported by 10.5% of patients given micronised progesterone. Significantly (p<0.05), more patients given dydrogesterone than micronised progesterone were satisfied with the tolerability of their treatment. There were no differences between the treatments with regard to liver function tests.
authors.affiliation: Department of ART, Institute of Reproductive Medicine, Calcutta 700106, West Bengal, India. bnc@irmbnc.org
authors.forename: Baidya Nath
authors.initials: BN
authors.lastname: Chakravarty
authors.forename: Hasibul Hasan
authors.initials: HH
authors.lastname: Shirazee
authors.forename: Purvita
authors.initials: P
authors.lastname: Dam
authors.forename: Sourendra Kanta
authors.initials: SK
authors.lastname: Goswami
authors.forename: Ratna
authors.initials: R
authors.lastname: Chatterjee
authors.forename: Sanghamitra
authors.initials: S
authors.lastname: Ghosh
mesh_terms: D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D004394:Dydrogesterone / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage* / Q000494:pharmacology; D011446:Prospective Studies; D027724:Reproductive Techniques, Assisted; D020554:Sperm Injections, Intracytoplasmic / Q000187:drug effects
chemical_list: D006063:Chorionic Gonadotropin; D011374:Progesterone; D004394:Dydrogesterone